Pre- and postoperative chemotherapy including Bevacizumab in potentially curable metastatic colorectal Cancer (mCRC). A multicenter, prospective Phase I/II academic trial.

ABSTRACT: primary objective: Resectability (R0) rate after neoadjuvant XELOX+Avastin in potentially resectable mCRC primary objective: Resectability (R0) rate after neoadjuvant Avastin in potentially resectable mCRCsecondary objectives: Feasibility with regards to GI bleeding and wound healing complications after surgery of liver metastases, general safety, ORR, RFS, OS

DISEASE(S):  patients With Histologically Confirmed Diagnosis Of Metastatic Colorectal Cancer (crc) Including Potentially Resectable Liver Metastases, Untreated Yet With Chemotherapy For Metastatic Disease

PROVIDER: 2520675 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR